BMRN 주식 개요 는 생명을 위협하는 심각한 희귀 질환 및 질환을 앓고 있는 사람들을 위한 치료법을 개발하고 상용화하는 데 주력하고 있습니다. 자세한 내용
보상 위험 분석 BMRN 위험성 검사를 통과했습니다.
모든 위험 점검 보기 {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
BioMarin Pharmaceutical Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 BioMarin Pharmaceutical 과거 주가 현재 주가 US$60.88 52주 최고치 US$88.06 52주 최저치 US$56.94 베타 0.28 1개월 변경 -6.02% 3개월 변경 사항 -2.84% 1년 변경 사항 -24.82% 3년 변화 -24.22% 5년 변화 -25.63% IPO 이후 변화 -23.37%
최근 뉴스 및 업데이트
New minor risk - Earnings quality Nov 01
Third quarter 2024 earnings released: EPS: US$0.56 (vs US$0.21 in 3Q 2023) Oct 30
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024 Oct 30
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting Sep 18
Investor sentiment deteriorates as stock falls 16% Sep 16
Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027 Sep 05 더 많은 업데이트 보기
New minor risk - Earnings quality Nov 01
Third quarter 2024 earnings released: EPS: US$0.56 (vs US$0.21 in 3Q 2023) Oct 30
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024 Oct 30
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting Sep 18
Investor sentiment deteriorates as stock falls 16% Sep 16
Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027 Sep 05
BioMarin Pharmaceutical Inc. Announces Management Changes Aug 21
Second quarter 2024 earnings released: EPS: US$0.56 (vs US$0.30 in 2Q 2023) Aug 06
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease Jul 25
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index Jul 03 Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children
First quarter 2024 earnings released: EPS: US$0.47 (vs US$0.27 in 1Q 2023) Apr 25
BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024 Apr 10
Insider recently sold €2.8m worth of stock Mar 08
Biomarin Announces Board Changes, Effective May 20, 2024 Mar 07
Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022) Feb 23
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024 Feb 23
Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024 Jan 12
BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023 Dec 21
New major risk - Share price stability Nov 07 Biomarin Pharmaceutical Inc. Announces CEO Changes
Third quarter 2023 earnings released: EPS: US$0.21 (vs US$0.036 loss in 3Q 2022) Nov 02
BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023 Nov 02
U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia Oct 21
Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting Sep 22
BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe Aug 31
Executive VP recently sold €899k worth of stock Aug 10
Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.15 in 2Q 2022) Aug 01 Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023
Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc Jul 13
U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A Jun 30
BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program Jun 23
First quarter 2023 earnings released: EPS: US$0.27 (vs US$0.66 in 1Q 2022) Apr 29
Full year 2022 earnings released: EPS: US$0.76 (vs US$0.35 loss in FY 2021) Mar 01
BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 08
Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis Jan 09
BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2 Jan 04
BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A Nov 24
BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program Nov 08
BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022 Oct 27
FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A Oct 13
BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022 Oct 05
BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC) Aug 25
Insider recently sold €586k worth of stock Aug 13
Second quarter 2022 earnings released: EPS: US$0.15 (vs US$0.071 in 2Q 2021) Aug 04
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2022 Aug 04
BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A Jun 25
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed Jun 22
BioMarin Pharmaceutical Inc. Announces Favorable Results from Global Phase 2 Study of Voxzogo™ (Vosoritide) for Injection in Infants and Young Children with Achondroplasia At the Endocrine Society Annual Meeting Jun 14
BioMarin Pharmaceutical Inc. Announces Durable Hemostatic Efficacy Maintained over 6 Years in Ongoing Phase 1 2 Study of Valoctocogene Roxaparvovec Jun 01
BioMarin Pharmaceutical Inc. Announces Executive Appointments May 06
First quarter 2022 earnings released: EPS: US$0.66 (vs US$0.096 in 1Q 2021) Apr 28 BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2022 Apr 28
BioMarin Pharmaceutical Inc., Annual General Meeting, May 24, 2022 Apr 13
Independent Director recently sold €446k worth of stock Mar 06
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 25
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year of 2022 Feb 24
BioMarin Pharmaceutical Inc. Provides Updates on Progress in Gene Therapy Programs Feb 18
BioMarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control in the Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At Two Year Analysis Jan 10
ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action Dec 08
Chairman & CEO recently sold €116k worth of stock Dec 04
Third quarter 2021 earnings released: US$0.20 loss per share (vs US$4.33 profit in 3Q 2020) Oct 29
Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.16 loss in 2Q 2020) Jul 29
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress Jul 20
European Medicines Agency Validates Biomarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Jul 16 BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Midcap Growth Index
BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close Jun 26
Independent Director Michael Grey has left the company Jun 05
European Medicines Agency Grants BioMarin Pharmaceutical Inc.'s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A May 25
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A May 20
BioMarin Pharmaceutical Inc. Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting May 13
First quarter 2021 earnings released: EPS US$0.096 (vs US$0.45 in 1Q 2020) May 01
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year of 2021 Apr 30
BioMarin Pharmaceutical Inc. Announces Data from the Open-Label Long-Term Extension of the Phase 3 Study Mar 21
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A Mar 10
BioMarin Pharmaceutical Inc. Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia Mar 05
Full year 2020 earnings released: EPS US$4.75 (vs US$0.13 loss in FY 2019) Feb 28
Revenue beats expectations Feb 28
New 90-day low: €62.99 Feb 27
BioMarin Pharmaceutical Inc. Appoints Maykin Ho to its Board of Directors Feb 19
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A Jan 11
BioMarin Pharmaceutical Inc. Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study Dec 23
Investor sentiment improved over the past week Dec 17
New 90-day high: €68.71 Dec 15
the Portnoy Law Firm Files Class Action Lawsuit on BioMarin Pharmaceutical Inc Nov 21
BioMarin Expands Vosoritide Clinical Program Nov 10
Third quarter 2020 earnings released: EPS US$4.33 Nov 07
Revenue beats expectations Nov 07
BioMarin Pharmaceutical Inc. Announces Revised Earnings Guidance for the Year 2020 Nov 06
New 90-day low: €61.22 Nov 05
Food and Drug Administration Accepts Biomarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia Nov 03
BioMarin Pharmaceutical Inc. Sues for Violations of the Federal Securities Laws Oct 29
BioMarin Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU Oct 08
BioMarin Pharmaceutical Inc. Appoints Kevin Eggan as Head of Research and Early Development Oct 06 주주 수익률 BMRN AT Biotechs AT 마켓 7D 1.1% -0.4% 3.0% 1Y -24.8% 16.9% 11.6%
전체 주주 수익률 보기
수익률 대 산업: BMRN 지난 1년 동안 16.9 %를 반환한 Austrian Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: BMRN 지난 1년 동안 11.6 %를 반환한 Austrian 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is BMRN's price volatile compared to industry and market? BMRN volatility BMRN Average Weekly Movement 3.5% Biotechs Industry Average Movement 7.6% Market Average Movement 4.0% 10% most volatile stocks in AT Market 6.4% 10% least volatile stocks in AT Market 2.0%
안정적인 주가: BMRN 지난 3개월 동안 Austrian 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: BMRN 의 주간 변동성 ( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 는 생명을 위협하는 심각한 희귀 질환 및 질환을 앓고 있는 사람들을 위한 치료제의 개발 및 상용화에 종사하고 있습니다. 회사의 상용 제품으로는 리소좀 저장 장애인 뮤코다당증(MPS) IV A형 치료를 위한 효소 대체 요법인 비미짐, MPS VI 환자를 위한 재조합 형태의 N-아세틸갈락토사민 4-설파타제인 나글라임, 유전성 대사 질환인 페닐케톤뇨증(PKU) 환자 치료에 사용되는 6R-BH4의 독점적 합성 경구 형태인 쿠반 등이 있습니다. 또한 피하 주사를 통해 혈중 페닐알라닌 농도를 낮추는 페길화 재조합 페닐알라닌 암모니아 분해 효소인 팔린지크와 바텐병의 한 형태인 세로이드 리포푸신증 2형 환자 치료를 위한 재조합 인간 트리펩티딜 펩티다제1인 브리뉴라가 상용 제품으로 포함되어 있습니다; 연골형성부전증 치료를 위한 1일 1회 주사제인 c형 나트리뇨 펩타이드 유사체 복스조고(Voxzogo), 자연적으로 발생하는 형태의 인간 효소 알파-L- 이두로니다아제와 동일하게 설계된 정제 단백질 알두라자임(Aldurazyme) 등이 있습니다.
자세히 보기 BioMarin Pharmaceutical Inc. 기본 사항 요약 BioMarin Pharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요? BMRN 기본 통계 시가총액 €11.70b 수익(TTM ) €311.53m 수익(TTM ) €2.66b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) BMRN 손익 계산서(TTM ) 수익 US$2.75b 수익 비용 US$1.31b 총 이익 US$1.44b 기타 비용 US$1.12b 수익 US$322.29m
주당 순이익(EPS) 1.69 총 마진 52.35% 순이익 마진 11.71% 부채/자본 비율 11.0%
BMRN 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/11 07:55 장 마감 주가 2025/02/11 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 BioMarin Pharmaceutical Inc. 56 애널리스트 중 27 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Jack Allen Baird Ishan Majumdar Baptista Research Huidong Wang Barclays
53 더 많은 분석가 보기 
